<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36877">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02626455</url>
  </required_header>
  <id_info>
    <org_study_id>17833</org_study_id>
    <secondary_id>2015-001088-38</secondary_id>
    <nct_id>NCT02626455</nct_id>
  </id_info>
  <brief_title>Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)</brief_title>
  <acronym>CHRONOS-4</acronym>
  <official_title>A Phase III, Randomized, Double-blind, Controlled Multicenter Study of Intravenous PI3K Inhibitor Copanlisib in Combination With Standard Immunochemotherapy Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether copanlisib in combination with standard
      immunochemotherapy (rituximab in combination with bendamustine [R-B] and rituximab in
      combination with a 4 drug combination of cyclophosphamide, doxorubicin, vincristine and
      prednisone/prednisolone [R-CHOP]) is effective and safe compared with placebo in combination
      with standard immunochemotherapy (R-B or R-CHOP) in patients with relapsed iNHL who have
      received at least one, but at most three, lines of treatment, including rituximab and
      alkylating agents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients should be in need of and fit for immunochemotherapy and should not be resistant to
      rituximab (resistance defined as lack of response, or progression within 6 months of the
      last course of treatment with a rituximab containing regimen). This study will be composed
      of two parts: Safety run-in and phase III part.

      The purpose of the safety run-in part of this study is to assess whether the drug being
      tested (copanlisib) in combination with standard immunochemotherapy (R-B or R-CHOP) is safe
      and at what dose level of the study drug (copanlisib - 45mg or 60 mg) patients are able to
      tolerate the study treatment combination. In addition to finding a safe and tolerable dose
      level for the phase III part of the study, efficacy will also be evaluated for patients that
      stay on the study treatment during the safety run-in. The phase III part of the study will
      start when the recommended dose of copanlisib in combination with R-CHOP and R-B has been
      defined and confirmed by sponsor, principal investigator and Data Monitoring Committee.

      A maximum of 24 patients will take part in the safety run-in part of this study. In the
      phase III part approximately 676 patients will be randomly assigned to blinded treatment
      arms of copanlisib plus R-B or R-CHOP or placebo plus R-B or R-CHOP.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation whether copanlisib in combination with standard immunochemotherapy, is superior to placebo and standard immunochemotherapy assessed by the prolongation of progression free survival (PFS) - applicable to Phase III part</measure>
    <time_frame>at 53 month</time_frame>
    <description>Progression free survival is defined as the time (in days) from randomization to Disease Progression or death from any cause (if no progression documented).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of the recommended Phase III dose (RP3D) of copanlisib in combination with standard immunochemotherapy assessed by the occurrence of dose-limiting toxicity s (DLTs) / adverse events (AEs) - applicable to safety run-in part</measure>
    <time_frame>at Cycle 1: 21 days or 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response rate (ORR)</measure>
    <time_frame>at 53 months</time_frame>
    <description>Proportion of patients who have a best overall response over the whole duration of the study (i.e. up to time of analysis of PFS) of complete response (CR) or partial response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of tumor response (DOR)</measure>
    <time_frame>at 53 months</time_frame>
    <description>Time (in days) from first observed tumor response (complete response [CR], very good partial response [VGPR], partial response [PR], or minor response [MR]) until PD or death from any cause, whichever is earlier. DOR will only be analyzed for patients with at least one CR, VGPR, PR, or MR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete tumor response rate (CRR)</measure>
    <time_frame>at 53 months</time_frame>
    <description>Proportion of patients who have a best overall response of CR during the study (i.e., up to time of analysis of PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tumor progression (TTP)</measure>
    <time_frame>at 53 months</time_frame>
    <description>Time from randomization to PD or death related to PD, whichever is earlier</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>at 53 months</time_frame>
    <description>The time (in days) from randomization until death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to deterioration in disease-related physical symptoms (DRS-P) of at least 3 points as measured by by the FLymSI-18 (Lymphoma Symptom Index -18) questionnaire</measure>
    <time_frame>at 53 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to improvement in DRS-P of at least 3 points, as measured by the FLymSI-18 questionnaire, will be evaluated for patients with a baseline DRS-P score of 30 points or less</measure>
    <time_frame>at 53 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next anti-lymphoma treatment (TTNT)</measure>
    <time_frame>at 53 months</time_frame>
    <description>Time from stop of study medication to start of new anti-lymphoma therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological and clinical indicators of treatment efficacy: Progression free survival (PFS)</measure>
    <time_frame>After Cycle 1: day 22 or 29 up to 12 months</time_frame>
    <description>Applicable to safety run-in phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological and clinical indicators of treatment efficacy:Objective tumor response rate (ORR)</measure>
    <time_frame>After Cycle 1: day 22 or 29 up to 12 months</time_frame>
    <description>Applicable to safety run-in phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological and clinical indicators of treatment efficacy:Duration of tumor response (DOR)</measure>
    <time_frame>After Cycle 1: day 22 or 29 up to 12 months</time_frame>
    <description>Applicable to safety run-in phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological and clinical indicators of treatment efficacy: Complete tumor response rate (CRR)</measure>
    <time_frame>After Cycle 1: day 22 or 29 up to 12 months</time_frame>
    <description>Applicable to safety run-in phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological and clinical indicators of treatment efficacy: Time to tumor progression (TTP)</measure>
    <time_frame>After Cycle 1: day 22 or 29 up to 12 months</time_frame>
    <description>Applicable to safety run-in phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological and clinical indicators of treatment efficacy: Time to next anti-lymphoma treatment (TTNT)</measure>
    <time_frame>After Cycle 1: day 22 or 29 up to 12 months</time_frame>
    <description>Applicable to safety run-in phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological and clinical indicators of treatment efficacy: Overall survival (OS)</measure>
    <time_frame>After Cycle 1: day 22 or 29 up to 12 months</time_frame>
    <description>Applicable to safety run-in phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>at 53 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological and clinical indicators of treatment efficacy: &quot;time to deterioration&quot; in disease-related symptoms - physical (DRS-P) will be assessed using the NCCN-FACT Lymphoma Symptom Index-18 (FLymSI-18) questionnaire</measure>
    <time_frame>After Cycle 1: day 22 or 29 up to 12 months</time_frame>
    <description>Applicable to safety run-in phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological and clinical indicators of treatment efficacy: Time to improvement&quot; in disease-related symptoms - physical (DRS-P) will be assessed using the FLymSI-18 questionnaire</measure>
    <time_frame>After Cycle 1: day 22 or 29 up to 12 months</time_frame>
    <description>Applicable to safety run-in phase</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">676</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>Copanlisib + R-B or R-CHOP / Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of copanlisib with standard immunochemotherapy (rituximab and bendamustine) [R-B] or rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone [R-CHOP] (safety run-in and phase III)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + R-B or R-CHOP / Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Combination of placebo and R-B or R-CHOP (phase III only)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copanlisib (BAY 80-6946)</intervention_name>
    <description>Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. For patients on R-B dosing of copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered and then rituximab followed by bendamustine. For patients on R-CHOP dosing of copanlisib will be administered on Days 1 and 8 of each 21-day cycle. Copanlisib will be administered before rituximab followed by cyclophosphamide, doxorubicin and vincristine infusions. Prednisone/prednisolone tablets to be taken for 5 days.</description>
    <arm_group_label>Copanlisib + R-B or R-CHOP / Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered as per copanlisib described above. Applies to the phase III part of the study only.</description>
    <arm_group_label>Placebo + R-B or R-CHOP / Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab is administered as an infusion at a dose of 375 mg/m2 body surface on Day 1 of each 28-day cycle for patients assigned to R-B and on Day 2 of each 21-day cycle for patients assigned to R-CHOP.</description>
    <arm_group_label>Copanlisib + R-B or R-CHOP / Arm 1</arm_group_label>
    <arm_group_label>Placebo + R-B or R-CHOP / Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide is administered as an infusion at a dose of 750 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP</description>
    <arm_group_label>Copanlisib + R-B or R-CHOP / Arm 1</arm_group_label>
    <arm_group_label>Placebo + R-B or R-CHOP / Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin is administered as an infusion at a dose of 50 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP</description>
    <arm_group_label>Copanlisib + R-B or R-CHOP / Arm 1</arm_group_label>
    <arm_group_label>Placebo + R-B or R-CHOP / Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Vincristine is administered as an infusion at a dose of 1.4 mg/m2 body surface (maximum dose 2.0 mg) on Day 2 of each 21-day cycle for patients assigned to R-CHOP</description>
    <arm_group_label>Copanlisib + R-B or R-CHOP / Arm 1</arm_group_label>
    <arm_group_label>Placebo + R-B or R-CHOP / Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Bendamustine is administered as an infusion at a dose of 90 mg/m2 body surface on Day 1 and Day 2 for patients assigned to R-B</description>
    <arm_group_label>Copanlisib + R-B or R-CHOP / Arm 1</arm_group_label>
    <arm_group_label>Placebo + R-B or R-CHOP / Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone is given as 100 mg tablets daily from Day 2 to Day 6 for patients assigned to R-CHOP</description>
    <arm_group_label>Copanlisib + R-B or R-CHOP / Arm 1</arm_group_label>
    <arm_group_label>Placebo + R-B or R-CHOP / Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of CD20 positive iNHL with histological subtype
             limited to:

               -  Follicular lymphoma G1-2-3a

               -  Small lymphocytic lymphoma with absolute lymphocyte count &lt;5x10E9/L at study
                  entry

               -  Lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM)

               -  Marginal zone lymphoma (splenic, nodal, or extranodal)

          -  Patients must have relapsed after at least 1 but at most 3 prior lines of therapy,
             including rituximab and alkylating agents. A previous regimen is defined as one of
             the following: at least 2 months of single-agent therapy; at least 2 consecutive
             cyclesof polychemotherapy; autologous transplant; radioimmunotherapy. Previous
             exposure to other PI3Ki is acceptable provided there is no resistance.

          -  Non-WM must have at least one bi-dimensionally measurable lesion (that has not been
             previously irradiated) according to the Lugano Classification.

          -  Patients affected by WM who do not have at least one bi-dimensionally measurable
             lesion in the baseline radiologic assessment must have measurable disease, defined as
             presence of immunoglobulin M (IgM) paraprotein with a minimum IgM level ≥ 2 x upper
             limit of normal (ULN) and positive immunofixation test.

          -  Male or female patients ≥ 18 years of age

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

          -  Life expectancy of at least 3 months

          -  Availability of fresh tumor tissue and/or archival tumor tissue at Screening

          -  Adequate baseline laboratory values collected within 7 days of starting the study
             treatment

          -  Left ventricular ejection fraction (LVEF) ≥ 50%

        Exclusion Criteria

          -  Histologically confirmed diagnosis of follicular lymphoma grade 3b or transformed
             disease, or chronic lymphocytic leukemia.

          -  Rituximab resistance at any line of therapy (resistance defined as lack of response,
             or progression within 6 months of the last course of treatment with a rituximab
             containing regimen

          -  History or concurrent condition of interstitial lung disease and/or severely impaired
             lung function (as judged by the investigator)

          -  Known lymphomatous involvement of the central nervous system

          -  HbA1c &gt; 8.5% at Screening

          -  Known history of human immunodeficiency virus (HIV) infection

          -  Hepatitis B (HBV) or hepatitis C (HCV) infection. Patients positive for Hepatitis B
             surface antigen (HBsAg or HBcAb) will be eligible if they are negative for HBV-DNA,
             these patients should receive prophylactic antiviral therapy. Patients positive for
             anti-HCV antibody will be eligible if they are negative for HCV-RNA.

          -  Uncontrolled hypertension despite optimal medical management (per investigator´s
             assessment)

          -  Congestive heart failure &gt; New York Heart Association (NYHA) class 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bayer US toll-free number</last_name>
    <phone>(+)1-888-84 22937</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401-5799</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kurralta Park</city>
        <state>South Australia</state>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Prahran</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Changchun</city>
        <zip>130012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tianjin</city>
        <zip>300121</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 10</city>
        <zip>100 34</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Limoges Cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Augsburg</city>
        <state>Bayern</state>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hongkong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Holon</city>
        <zip>5810001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <zip>93-513</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tainan</city>
        <zip>70428</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Tyne and Wear</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>China</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Greece</country>
    <country>Turkey</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 10, 2017</lastchanged_date>
  <firstreceived_date>November 3, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clinical trial, Phase III</keyword>
  <keyword>Phosphatidylinositol-3-kinase</keyword>
  <keyword>Non-Hodgkin's lymphoma</keyword>
  <keyword>Indolent B-cell non-Hodgkin's lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
